Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. EVAX
stocks logo

EVAX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
2.50M
-17.14%
-0.010
-85.71%
0.00
-100%
-0.255
-49%
--
--
-0.250
-75%
Estimates Revision
The market is revising Upward the revenue expectations for Evaxion A/S (EVAX) for FY2025, with the revenue forecasts being adjusted by 198.53% over the past three months. During the same period, the stock price has changed by 81.16%.
Revenue Estimates for FY2025
Revise Upward
up Image
+198.53%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-33.33%
In Past 3 Month
Stock Price
Go Up
up Image
+81.16%
In Past 3 Month
Wall Street analysts forecast EVAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EVAX is 12.33 USD with a low forecast of 10.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast EVAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EVAX is 12.33 USD with a low forecast of 10.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.290
sliders
Low
10.00
Averages
12.33
High
16.00
Current: 5.290
sliders
Low
10.00
Averages
12.33
High
16.00
JonesResearch
NULL -> Buy
initiated
$10
2025-10-29
Reason
JonesResearch
Price Target
$10
2025-10-29
initiated
NULL -> Buy
Reason
JonesResearch initiated coverage of Evaxion Biotech with a Buy rating and $10 price target. The firm says Evaxion is a clinical-stage company leveraging its AIdriven platform to develop vaccines. The company's Phase 2 data in melanoma showed a durable clinical benefit and sustained immune response at the two-year cutoff, the analyst tells investors in a research note.
Lake Street
Thomas Flaten
Buy
maintain
$6 -> $11
2025-10-20
Reason
Lake Street
Thomas Flaten
Price Target
$6 -> $11
2025-10-20
maintain
Buy
Reason
Lake Street analyst Thomas Flaten raised the firm's price target on Evaxion Biotech (EVAX) to $11 from $6 and keeps a Buy rating on the shares after the company announced two-year Phase 2 data for its personalized cancer vaccine, EVX-01, in advanced melanoma. The two-year EVX-01 data and Merck's (MRK) option exercise for EVX-B3 further validate Evaxion's platform, the analyst tells investors.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$14 -> $16
2025-09-25
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$14 -> $16
2025-09-25
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Evaxion Biotech (EVAX) to $16 from $14 and keeps a Buy rating on the shares. The firm notes that as it expected, Merck (MRK) exercised its option to in-license EVX-B3, Evaxion's discovery-stage vaccine candidate against an undisclosed bacterial pathogen. Wainwright's positive takeaways are threefold, namely Merck's option exercise extends Evaxion's cash runway to the first half of 2027, carrying EVAX through several milestones across its infectious disease and oncology programs; Merck's decision to extend and expand review of the EVX-B2 program strengthens likelihood that it could choose to in-license the program in the first half of 2026; and this represents the second deal expansion with Merck, already a 20% owner of Evaxion, and thus deepens validation for the company's AI-Immunology target discovery platform.
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Reiterates
$14
2025-04-02
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Price Target
$14
2025-04-02
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Reiterates
$14
2025-02-20
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Price Target
$14
2025-02-20
Reiterates
Strong Buy
Reason
Lake Street
Thomas Flaten
Strong Buy
Maintains
$35 → $6
2025-02-04
Reason
Lake Street
Thomas Flaten
Price Target
$35 → $6
2025-02-04
Maintains
Strong Buy
Reason
Evaxion Biotech announced the pricing of a public offering of an aggregate of 3,997,361 of its American Depositary Shares and warrants to purchase up to 50% of the ADSs offered at a combined public offering price of $2.71 per ADS with one accompanying warrant for each two ADSs. MSD Global Health Innovation Fund, who became an Evaxion shareholder in December 2023, is also participating in this offering along with healthcare-focused investment funds. There is also participation from Evaxion's Board of Directors and Management. The warrants will have an exercise price of $2.71 per ADS, will be exercisable immediately upon issuance and will expire five years following the date of issuance. Each ADS represents fifty ordinary shares of the company. The closing of the offering is expected to occur on or about January 31, 2025, subject to the satisfaction of customary closing conditions. Lake Street Capital Markets and Jones are acting as the exclusive placement agents for the offering. The gross proceeds to the company from the offering are expected to be $10.8M, before deducting the placement agent's fees and other offering expenses payable by the company. The company intends to use the net proceeds of this offering to advance the company's preclinical and clinical pipeline, and for continuing operating expenses and working capital.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Evaxion A/S (EVAX.O) is -10.17, compared to its 5-year average forward P/E of -4.77. For a more detailed relative valuation and DCF analysis to assess Evaxion A/S 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.77
Current PE
-10.17
Overvalued PE
0.50
Undervalued PE
-10.05

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.55
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.08
Undervalued EV/EBITDA
-3.03

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
11.14
Current PS
0.00
Overvalued PS
27.73
Undervalued PS
-5.45
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

EVAX News & Events

Events Timeline

(ET)
2025-11-20
08:07:59
Evaxion Biotech Reveals Data on CMV Vaccine Program EVX-V1
select
2025-11-06 (ET)
2025-11-06
07:42:48
Evaxion Biotech announces Q3 earnings per share of 1 cent compared to a loss of 4 cents last year.
select
2025-11-03 (ET)
2025-11-03
09:06:25
Evaxion Biotech Enhances Research and Development Pipeline with EVX-04
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
12-02NASDAQ.COM
Post-Market Highlights: Jasper, NRx, Unicycive, Spruce, Evaxion, Solana, and Protara See Gains After Trading Hours

  • Biotech Gains in After-Hours Trading: Several biotechnology and pharmaceutical companies saw significant stock price increases in after-hours trading, driven by corporate updates and upcoming events.

  • Jasper Therapeutics' Webinar Announcement: Jasper Therapeutics, Inc. experienced a 21.51% surge after announcing a webinar to discuss findings from the BEACON study and preliminary data from the ETESIAN study.

  • NRx Pharmaceuticals' Presentation at NobleCon21: NRx Pharmaceuticals, Inc. rose 13.39% following the announcement that its CEO will present updates on the company's focus and clinical revenue at an upcoming conference.

  • Protara Therapeutics' Conference Call: Protara Therapeutics, Inc. gained 5.04% after revealing plans for a conference call to discuss interim data from its Phase 2 trial for bladder cancer, with findings to be presented at a major urology meeting.

[object Object]
Preview
9.0
11-08Newsfilter
Evaxion unveils new immune findings from phase 2 trial of AI-crafted personalized cancer vaccine EVX-01

  • New Data Presentation: Evaxion A/S presented new biomarker and immune data for its personalized cancer vaccine EVX-01 at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, building on previously reported two-year clinical efficacy data from a phase 2 trial.

  • Vaccine Mechanism: EVX-01, developed using Evaxion's AI-Immunology™ platform, targets multiple neoantigens to induce immune responses, particularly focusing on the characterization of circulating T-cell subsets in patients with advanced melanoma treated alongside KEYTRUDA®.

  • Clinical Insights: The new data indicates that clinical responses in some patients were associated with a rapid and sustained induction of EVX-01-specific T-cells, enhancing the understanding of the immune responses elicited by the vaccine.

  • Company Commitment: Evaxion aims to transform patient care through innovative immunotherapies, leveraging its AI technology to develop personalized vaccines for cancer and infectious diseases, while also navigating various business and regulatory challenges.

[object Object]
Preview
9.5
10-31Newsfilter
Evaxion to Release Business Update and Q3 2025 Financial Results on November 6, 2025

  • Business Update Announcement: Evaxion A/S will provide a business update and report its Q3 2025 financial results on October 31, 2025, before the Nasdaq opening, followed by a conference call and webcast at 14:30 CET/08:30 EST.

  • Public Participation: The conference call is free and open to the public, with registration required to receive dial-in details, and a recording of the webcast will be available on Evaxion's website shortly after the event.

  • Company Overview: Evaxion A/S is a TechBio company utilizing its AI-Immunology™ platform to develop innovative vaccines targeting cancer, bacterial diseases, and viral infections, aiming to transform patient care.

  • Forward-Looking Statements: The announcement includes forward-looking statements regarding the company's future performance and potential risks, emphasizing the uncertainty surrounding financial conditions, product development, and market acceptance.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Evaxion A/S (EVAX) stock price today?

The current price of EVAX is 5.29 USD — it has increased 3.73 % in the last trading day.

arrow icon

What is Evaxion A/S (EVAX)'s business?

Evaxion A/S, formerly known as Evaxion Biotech A/S, is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.

arrow icon

What is the price predicton of EVAX Stock?

Wall Street analysts forecast EVAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EVAX is 12.33 USD with a low forecast of 10.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Evaxion A/S (EVAX)'s revenue for the last quarter?

Evaxion A/S revenue for the last quarter amounts to 7.49M USD, increased 148.33 % YoY.

arrow icon

What is Evaxion A/S (EVAX)'s earnings per share (EPS) for the last quarter?

Evaxion A/S. EPS for the last quarter amounts to 0.01 USD, decreased -105.56 % YoY.

arrow icon

What changes have occurred in the market's expectations for Evaxion A/S (EVAX)'s fundamentals?

The market is revising Upward the revenue expectations for Evaxion A/S (EVAX) for FY2025, with the revenue forecasts being adjusted by 198.53% over the past three months. During the same period, the stock price has changed by 81.16%.
arrow icon

How many employees does Evaxion A/S (EVAX). have?

Evaxion A/S (EVAX) has 46 emplpoyees as of December 05 2025.

arrow icon

What is Evaxion A/S (EVAX) market cap?

Today EVAX has the market capitalization of 44.45M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free